Key result
Detectable TTV-DNA at liver transplant is linked to ~99% lower risk of acute cellular rejection.
Why the study?
The relationship between torque teno virus load and acute rejection after orthotopic liver transplantation was unclear and warranted investigation.
Does detectable TTV-DNA at transplantation predict a lower risk of acute rejection in orthotopic liver transplant recipients?
Population
39 patients after orthotopic liver transplantation and 74 healthy controls in the Swiss Transplant Cohort Study
Comparison
Detectable versus undetectable TTV-DNA plasma levels at transplantation
Design
Retrospective cohort study
Follow-up
1 year
Authors
Loading...
May support TTV-DNA as a rejection-risk biomarker in liver transplant; hypothesis-generating and requires prospective validation before practice change.
Cohort (n=113)
Yes
Does detectable TTV-DNA at transplantation predict a lower risk of acute rejection in orthotopic liver transplant recipients?
Hazard Ratio: 0.009 (95% CI 0.001–0.092)
Absolute Event Rate: 21% vs 70%
p-value: p=0.00008
Detectable Torque Teno Virus (TTV) DNA at the time of liver transplantation is associated with a significantly reduced risk of acute cellular rejection at 1 year, suggesting its potential as a biomarker for immunocompetence.
Simonetta et al. (2017) conducted a cohort in Orthotopic liver transplantation (n=113). Detectable TTV-DNA at transplantation vs. Undetectable TTV-DNA at transplantation was evaluated on 1-year cumulative incidence of biopsy-proven acute cellular graft rejection (HR 0.009, 95% CI 0.001-0.092, p=0.00008). Detectable TTV-DNA at liver transplantation was associated with a significantly lower 1-year incidence of acute cellular rejection compared to undetectable levels (21% vs 70%; HR 0.009, P=0.00008).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: